The global Dolutegravir market stood at nearly 20 thousand tonnes in 2023 and is anticipated to grow at a CAGR of 4.9% during the forecast period until 2034.
Dolutegravir operates within the class of HIV integrase inhibitors, a group of medications designed to combat the human immunodeficiency virus (HIV). Its primary function involves diminishing the presence of HIV in the bloodstream while simultaneously bolstering the population of immune cells crucial for combating infections within the body. Dolutegravir, when combined with other drugs, is employed in the treatment of human immunodeficiency virus (HIV) infection among adults and children aged four weeks and older, weighing at least 3 kilograms. Additionally, it is utilized alongside Rilpivirine (Edurant) in specific adults to substitute their existing HIV medication after a minimum of six months of treatment. Prior to initiating dolutegravir treatment, it's crucial to inform healthcare provider if you have any allergies to dolutegravir or other medications, a history of liver issues such as hepatitis B or hepatitis C infections, kidney problems, or any other underlying medical conditions.
The global Dolutegravir market is driven the persistent increase in HIV prevalence globally, particularly in regions with limited healthcare access. Its proven clinical effectiveness in suppressing HIV replication and enhancing immune function positions it as a leading choice in HIV treatment regimens. Moreover, evolving treatment guidelines, favour for Dolutegravir-based therapies due to their superior efficacy and safety profiles. The presence of patent exclusivity and market exclusivity further solidifies Dolutegravir's market position, allowing pharmaceutical companies to maintain pricing power and market share. Initiatives aimed at expanding access to HIV treatment, such as the "Treat All" strategy by the World Health Organization, are expected to drive demand for Dolutegravir in low- and middle-income countries. Additionally, the trend towards combination therapies, incorporating Dolutegravir alongside other antiretroviral drugs, offers a comprehensive approach to HIV management and reduces the risk of drug resistance. Patient preference for once-daily dosing regimens, offered by Dolutegravir, enhances treatment adherence and satisfaction among individuals living with HIV. Moreover, government funding and support for HIV treatment programs, including procurement initiatives and subsidies, contribute significantly to the market growth of Dolutegravir, particularly in public health systems. The global Dolutegravir market is likely to reach approximately 34 thousand tonnes in 2034.
Regionally, North America is a prominent consumer of Dolutegravir and is anticipated to sustain this position in the foreseeable future. This prominence is attributed to several factors. Firstly, North America has a relatively high prevalence of HIV/AIDS compared to other regions, necessitating a robust demand for effective antiretroviral treatments like Dolutegravir. Additionally, the region benefits from advanced healthcare infrastructure and research capabilities, facilitating widespread access to innovative HIV therapies. Moreover, favourable regulatory frameworks and reimbursement policies support the adoption of Dolutegravir in healthcare systems across North America. Furthermore, the presence of prominent pharmaceutical companies and research institutions in the region fosters ongoing advancements in HIV treatment, driving the continued consumption of Dolutegravir. Importantly, public health initiatives and advocacy efforts further contribute to the sustained demand for Dolutegravir, ensuring comprehensive HIV management and care for affected individuals in North America.
Based on end-use applications, the global Dolutegravir market is segmented into HIV-1 Infection, and Others. Furthermore, with this medication, alongside the adoption of safer sexual practices and lifestyle modifications, can further mitigate the risk of transmitting the HIV virus to other individuals.
Major players in the Global Dolutegravir market are ViiV Healthcare (GSK), Shanghai Desano Pharmaceuticals, Mylan, Aurobindo Pharma, LAURUS Labs, Adcock Ingram Limited, and Others.
Years considered for this report:
Historical Period: 2015- 2022
Base Year: 2023
Estimated Year: 2024
Forecast Period: 2025-2034
This report will be delivered on an online digital platform with one-year subscription and quarterly update.
Objective of the Study:
• To assess the demand-supply scenario of Dolutegravir which covers production, demand and supply of Dolutegravir market in the globe.
• To analyse and forecast the market size of Dolutegravir
• To classify and forecast Global Dolutegravir market based on end-use and regional distribution.
To extract data for Global Dolutegravir market, primary research surveys were conducted with Dolutegravir manufacturers, suppliers, distributors, wholesalers, and traders. While interviewing, the respondents were also inquired about their competitors. Through this technique, ChemAnalyst was able to include manufacturers that could not be identified due to the limitations of secondary research. Moreover, ChemAnalyst analyzed various segments and projected a positive outlook for Global Dolutegravir market over the coming years.
ChemAnalyst calculated Dolutegravir demand across the globe by analyzing the volume of Dolutegravir consumed by the End-Use applications and the forecast is calculated based on the growth rate of end-use industries. ChemAnalyst sourced these values from industry experts and company representatives and externally validated them by analyzing the historical sales data of respective manufacturers to determine the overall market size. Various secondary sources such as company websites, association reports, annual reports, etc., were also studied by ChemAnalyst.
Key Target Audience:
• Dolutegravir manufacturers and other stakeholders
• Organizations, forums and alliances related to Dolutegravir distribution
• Government bodies such as regulating authorities and policy makers
• Market research organizations and consulting companies
The study is useful in providing answers to several critical questions that are important for industry stakeholders such as Dolutegravir manufacturers, customers and policy makers. The study would also help them to target the growing segments over the coming years, thereby aiding the stakeholders in taking investment decisions and facilitating their expansion.
Report Scope:
In this report, Global Dolutegravir market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Attribute
Details
Market size Volume in 2023
20 thousand tonnes
Market size Volume in 2034
34 thousand tonnes
Growth Rate
CAGR of 4.9% from 2024 to 2034
Base year
2023
Estimated year
2024
Historical Data
2015 – 2022
Forecast period
2025 – 2034
Quantitative units
Demand in thousand tonnes and CAGR from 2024 to 2034
Report coverage
Industry Market Size, Capacity by Company, Capacity by Location, Operating Efficiency, Production by Company, Demand by Type, Demand by End-Use Application, Demand by Region, Demand by Distribution Channel, Demand-Supply Gap, Company Share, Manufacturing Process.
Segments covered
By End-Use Application: (High Blood Pressure, Heart Disease, and Others)
By Sales Channel: (Direct Sale and Indirect Sale)
Regional scope
North America, Europe, Asia Pacific, Middle East and Africa, and South America.
I am satisfied with overall performance of ChemAnalyst. Weekly updates before the final report were especially helpful and reassuring. Additional requests on the interim and/or final reports were handled in a swift and professional manner
Mr.Shin Dosho
Member - Board of Directors
Osaka Gas Co. Ltd
Disruption Tracker
Disruption Tracker reflect the major shutdown on monthly basis which will help you in
tracking the inventory management and smooth functioning of business. Unforeseen shutdowns and disruptions
resulting in a loss of production capacity to impact the bottom line. The capacity tracker provides industries
with a global view of production and consumption capacity loss that reflects the corresponding conversion factors.
It also highlights the immediate impact on supply due to planned and unplanned outages as well as upcoming start-up
of new capacities. Additionally, it emphasizes how each shutdown—whether due to a maintenance turnaround or a case
of force majeure, affects the plant's operating rate for the given duration. Disruption tracker gives a clear insight
into the worldwide outages affecting the commodity of interest. With every shutdown, it also reflects the impact on
supply of the product in the market at a Global level.
What was the net market size of Dolutegravir in terms of volume in 2023?
Ans:
The global market size of Dolutegravir has reached approximately 20 thousand tonnes in 2023.
Q2.
Which region is a prominent consumer of Dolutegravir?
Ans:
North America is a prominent consumer of Dolutegravir globally.
Q3.
Do you offer single or multiuser license?
Ans:
Online Access 12 Months – Single User License (Up to 3 users can access the database)
Online Access 12 Months – Enterprise License (Up to 10 Users can access the database)
Q4.
Will I get access to the analyst who authored this report?
Ans:
You will have 24/7 access to the analyst during the subscription period.
Our Solutions
Custom Research
We at ChemAnalyst provide tailor-made solutions to our clients based on their requirements which help them in building and expanding their business by developing customized strategy such as sales strategy, GTM Strategy, product portfolio and new product development. Our dedicated team helps clients in getting the best solution for their requirements. We at ChemAnalyst look forward to serving our clients for long term association.
Techno Economic Feasibility Report (TEFR)
ChemAnalyst provide TEFR reports which include market sizing, plant cost (ISBL and OSBL units), financial modelling, covering all the major financial calculations and ratios including production cost, IRR, major technology, licensing fee (if required), and others fixed and variable costs. TEFR reports will help the client to build greenfield project as well as brownfield expansion for a specific geography. Our Team of experts have delivered multiple TEFR reports which help clients in moving ahead of their business competition by grabbing the opportunity and expanding their business portfolio.
Price Benchmarking
Pricing benchmark report provides real-time data perpetuating current market scenarios, in a world that is changing at a rapid pace, having real-time prices is an imperative to make impactful insights and thereby informed decisions. The Price Benchmarking report provides pricing data for an individual market, or group of markets, which can be converted into localized insights and comparable listings. Benchmarking Reports help clients to make informed decisions by construing the data on several filters: region, country, category, grade and subsequently increasing their brand presence. Clients majorly require pricing benchmarks when they opt for a competitive pricing strategy.